Browsing by Author "Wu, Tung-Ho"

Now showing 1 - 4 of 4

Activation of Angiogenesis and Wound Healing in Diabetic Mice Using NO-Delivery Dinitrosyl Iron Complexes
(2019-10-01)
Chen, Yu-Jen
;
Wu, Shou-Cheng
;
Wang, Hsiang-Ching
;
Wu, Tung-Ho
;
Yuan, Shyng-Shiou F.
In diabetes, abnormal angiogenesis due to hyperglycemia and endothelial dysfunction impairs wound healing and results in high risks of diabetic foot ulcers and mortality. Alternative therapeutic methods were attempted to prevent diabetic complications through the activation of endothelial nitric oxide synthase. In this study, direct application of nitric oxide using dinitrosyl iron complexes (DNICs) to promote angiogenesis and wound healing under physiological conditions and in diabetic mice is investigated. Based on in vitro and in vivo studies, DNIC [Fe-2(mu-SCH2CH2OH)(2)(NO)(4)] (DNIC-1) with a sustainable NO-release reactivity (t(1/2) = 27.4 +/- 0.5 h at 25 degrees C and 16.8 +/- 1.8 h at 37 degrees C) activates the NO-sGC-cGMP pathway and displays the best proangiogenesis activity overwhelming other NO donors and the vascular endothelial growth factor. Moreover, this pro-angiogenesis effect of DNIC-1 restores the impaired angiogenesis in the ischemic hind limb and accelerates the recovery rate of wound closure in diabetic mice. This study translates synthetic DNIC-1 into a novel therapeutic agent for the treatment of diabetes and highlights its sustainable (NO)-N-center dot-release reactivity on the activation of angiogenesis and wound healing.
Development of a Mucin4-Targeting SPIO Contrast Agent for Effective Detection of Pancreatic Tumor Cells in Vitro and in Vivo
(2013-11-28)
Wu, Shou-Cheng
;
Chen, Yu-Jen
;
Lin, Yi-Jan
;
Wu, Tung-Ho
;
Wang, Yun-Ming
In search of a unique and reliable contrast agent targeting pancreatic adenocarcinoma, new multifunctional nanoparticles (MnMEIO-silane-NH2-(MUC4)-mPEG NPs) were successfully developed in this study. Mucin4-expression levels were determined through different imaging studies in a panel of pancreatic tumor cells (HPAC, BxPC-3, and Panc-1) both in vitro and in vivo studies. The in vitro T-2-weighted MR imaging study in HPAC and Panc-1 tumor cells treated with NPs showed -89.1 +/- 5.7% and -0.9 +/- 0.2% contrast enhancement, whereas in in vivo study, it is found to be -81.5 +/- 4.5% versus -19.6 +/- 5.2% (24 h postinjection, 7.0 T), respectively. The T-2-weighted MR and optical imaging studies revealed that the novel agent can specifically and effectively target to mucin4-expressing tumors in nude mice. Hence, it is suggested that MnMEIO-silane-NH2-(MUC4)-mPEG NPs are able to provide an efficient and targeted delivery of MUC4 antibodies to mucin4-expressing pancreatic tumors.
Humanized bispecific antibody (mPEG x HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer
(2020-08-27)
Cheng, Yi-An
;
Wu, Tung-Ho
;
Wang, Yun-Ming
;
Cheng, Tian-Lu
;
Chen, I-Ju
Background: Developing a universal strategy to improve the specificity and sensitivity of PEGylated nanoaparticles (PEG-NPs) for assisting in the diagnosis of tumors is important in multimodality imaging. Here, we developed the anti-methoxypolyethylene glycol (mPEG) bispecific antibody (BsAb; mPEG x HER2), which has dual specificity for mPEG and human epidermal growth factor receptor 2 (HER2), with a diverse array of PEG-NPs to confer nanoparticles with HER2 specificity and stronger intensity. Result: We used a one-step formulation to rapidly modify the nanoprobes with mPEG x HER2 and optimized the modified ratio of BsAbs on several PEG-NPs (Lipo-DiR, SPIO, Qdot and AuNP). The alpha HER2/PEG-NPs could specifically target MCF7/HER2 cells (HER2(++)) but not MCF7/neo1 cells (HER2(+/-)). The alpha HER2/Lipo-DiR and alpha HER2/SPIO could enhance the sensitivity of untargeted PEG-NPs on MCF7/HER2 (HER2(++)). In in vivo imaging, alpha HER2/Lipo-DiR and alpha HER2/SPIO increased the specific targeting and enhanced PEG-NPs accumulation at 175% and 187% on 24 h, respectively, in HER2-overexpressing tumors. Conclusion: mPEG x HER2, therefore, provided a simple one-step formulation to confer HER2-specific targeting and enhanced sensitivity and contrast intensity on HER2 positive tumors for multimodality imaging.
Label-Free Bimetallic In Situ-Grown 3D Nickel-Foam-Supported NH2-MIL-88B(Fe2Co)-MOF-based Impedimetric Immunosensor for the Detection of Cardiac Troponin I
(2020-07-22)
Palanisamy, Sathyadevi
;
Raja, Duraisamy Senthil
;
Subramani, Boopathi
;
Wu, Tung-Ho
;
Wang, Yun-Ming
In this study, a simple and competent metal-organic framework (MOF)-based nickel foam (NF)-supported three-dimensional (3D) immunosensor (Ab-NH2-MIL-88B-(Fe2Co)-MOF/NF) was constructed and utilized for the specific recognition of the biomarker cardiac troponin (I) (cTnI). In the present work, biosensor fabrication was progressed through the modification of the NF substrate with the MOF material (NH2-MIL-88B(Fe2Co)-MOF) to enable an amine-functionalized electrode. This amine-functionalized NF electrodes (NH2-MIL-88B(Fe2Co)-MOF/NF) were then biointerfaced with anti-cTnI antibodies, which ended up as Ab-NH2-MIL-88B(Fe2Co)-MOF/NF electrodes. Analytical executions of the constructed bioelectrode were investigated for the quantitative analysis of cTnI in both buffered and serum solutions. Then, the electrochemical studies were carried out using the electrochemical impedance spectroscopy (EIS) method by monitoring changes concerning the charge transfer resistance (R-ct) characteristics. The limit of detection (LOD) of the Ab-NH2-MIL-88B(Fe2Co)-MOF/NF immunosensor was achieved to be 13 fg/mL with great specificity. This kind of immunosensor imparts a new platform for the construction and application of MOF-hybrid 3D electrode materials with enhanced electrochemical behavior in cTnI sensing for the first time.